FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

About 1 in 8 men will be diagnosed with prostate cancer in their lifetime The average age at diagnosis is 67 Less than 1% of the 3.5 million men living with prostate cancer are expected to die from it ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

Use of relugolix among prostate cancer patients is associated with QoL, high treatment adherence rates, and low rates of ...

(WISH) — The American Cancer Society reports that about one in eight men will be diagnosed with prostate cancer in their lifetime. The average age of men who get diagnosed is 67. Today, less than 1% ...

A new study provides hope that smarter timing of cancer treatments could improve cure rates. The study's Principal Investigator, Dr. Robert Noble, Senior Lecturer at the Department of Mathematics, ...

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...

A PSMA PET scan found more recurrent prostate cancer at low PSA levels than a standard scan, helping guide more potentially curative treatment decisions. A newer type of prostate cancer scan called 64 ...

A new study provides hope that smarter timing of cancer treatments could improve cure rates. The study's Principal Investigator, Dr Robert Noble, Senior Lecturer at the Department of Mathematics, City ...

In the absence of trials, a post hoc analysis compared stereotactic body radiotherapy (SBRT) and high-dose-rate brachytherapy (HDR-BT) in intermediate-risk prostate cancer.